BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Brain cancer AND ERBB4, MGC138404, 2066, ENSG00000178568, Q15303, p180erbB4, HER4 AND Treatment
28 results:

  • 1. Multi-omics analyses of choroid plexus carcinoma cell lines reveal potential targetable pathways and alterations.
    Hesham D; On J; Alshahaby N; Amer N; Magdeldin S; Okada M; Tsukamoto Y; Hiraishi T; Imai C; Okuda S; Wakai T; Kakita A; Oishi M; El-Naggar S; Natsumeda M
    J Neurooncol; 2024 Jan; 166(1):27-38. PubMed ID: 38190092
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Neratinib for HER2-positive breast cancer with an overlooked option.
    Guo L; Shao W; Zhou C; Yang H; Yang L; Cai Q; Wang J; Shi Y; Huang L; Zhang J
    Mol Med; 2023 Oct; 29(1):134. PubMed ID: 37803271
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. The Yin and Yang of erbb4: Tumor Suppressor and Oncoprotein.
    Lucas LM; Dwivedi V; Senfeld JI; Cullum RL; Mill CP; Piazza JT; Bryant IN; Cook LJ; Miller ST; Lott JH; Kelley CM; Knerr EL; Markham JA; Kaufmann DP; Jacobi MA; Shen J; Riese DJ
    Pharmacol Rev; 2022 Jan; 74(1):18-47. PubMed ID: 34987087
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Circular RNA circ_0001162 promotes cell proliferation and invasion of glioma via the miR-936/erbb4 axis.
    Zhou D; Lin X; Wang P; Yang Y; Zheng J; Zhou D
    Bioengineered; 2021 Dec; 12(1):2106-2118. PubMed ID: 34057019
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Neratinib in the early-stage/extended adjuvant breast cancer patient.
    O'Shaughnessy JA; Isaacs C; O'Regan R
    Clin Adv Hematol Oncol; 2020 Aug; 18 Suppl 12(8):1-20. PubMed ID: 33843843
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Human epidermal growth factor receptor 2-positive metastatic breast cancer with novel epidermal growth factor receptor -ZNF880 fusion and epidermal growth factor receptor E114K mutations effectively treated with pyrotinib: A case report.
    Yue L; Wentao L; Xin Z; Jingjing H; Xiaoyan Z; Na F; Tonghui M; Dalin L
    Medicine (Baltimore); 2020 Dec; 99(51):e23406. PubMed ID: 33371069
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.
    Beauchamp RL; Erdin S; Witt L; Jordan JT; Plotkin SR; Gusella JF; Ramesh V
    J Biol Chem; 2021; 296():100157. PubMed ID: 33273014
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. The role of erbb4 in cancer.
    Segers VFM; Dugaucquier L; Feyen E; Shakeri H; De Keulenaer GW
    Cell Oncol (Dordr); 2020 Jun; 43(3):335-352. PubMed ID: 32219702
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Detection of circulating tumor DNA from non-small cell lung cancer brain metastasis in cerebrospinal fluid samples.
    Ma C; Yang X; Xing W; Yu H; Si T; Guo Z
    Thorac Cancer; 2020 Mar; 11(3):588-593. PubMed ID: 31944608
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Loss of Angelman Syndrome Protein E6AP Disrupts a Novel Antagonistic Estrogen-Retinoic Acid Transcriptional Crosstalk in Neurons.
    El Hokayem J; Weeber E; Nawaz Z
    Mol Neurobiol; 2018 Sep; 55(9):7187-7200. PubMed ID: 29388081
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Analysis of copy number loss of the erbb4 receptor tyrosine kinase in glioblastoma.
    Jones DC; Scanteianu A; DiStefano M; Bouhaddou M; Birtwistle MR
    PLoS One; 2018; 13(1):e0190664. PubMed ID: 29342193
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. A novel technique of serial biopsy in mouse brain tumour models.
    Rogers S; Hii H; Huang J; Ancliffe M; Gottardo NG; Dallas P; Lee S; Endersby R
    PLoS One; 2017; 12(4):e0175169. PubMed ID: 28394918
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Neuregulin-1 Administration Protocols Sufficient for Stimulating Cardiac Regeneration in Young Mice Do Not Induce Somatic, Organ, or Neoplastic Growth.
    Ganapathy B; Nandhagopal N; Polizzotti BD; Bennett D; Asan A; Wu Y; Kühn B
    PLoS One; 2016; 11(5):e0155456. PubMed ID: 27175488
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Chan A; Delaloge S; Holmes FA; Moy B; Iwata H; Harvey VJ; Robert NJ; Silovski T; Gokmen E; von Minckwitz G; Ejlertsen B; Chia SKL; Mansi J; Barrios CH; Gnant M; Buyse M; Gore I; Smith J; Harker G; Masuda N; Petrakova K; Zotano AG; Iannotti N; Rodriguez G; Tassone P; Wong A; Bryce R; Ye Y; Yao B; Martin M;
    Lancet Oncol; 2016 Mar; 17(3):367-377. PubMed ID: 26874901
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Translational Breast cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast cancer and brain Metastases.
    Freedman RA; Gelman RS; Wefel JS; Melisko ME; Hess KR; Connolly RM; Van Poznak CH; Niravath PA; Puhalla SL; Ibrahim N; Blackwell KL; Moy B; Herold C; Liu MC; Lowe A; Agar NY; Ryabin N; Farooq S; Lawler E; Rimawi MF; Krop IE; Wolff AC; Winer EP; Lin NU
    J Clin Oncol; 2016 Mar; 34(9):945-52. PubMed ID: 26834058
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Genetic alterations and their clinical implications in gastric cancer peritoneal carcinomatosis revealed by whole-exome sequencing of malignant ascites.
    Lim B; Kim C; Kim JH; Kwon WS; Lee WS; Kim JM; Park JY; Kim HS; Park KH; Kim TS; Park JL; Chung HC; Rha SY; Kim SY
    Oncotarget; 2016 Feb; 7(7):8055-66. PubMed ID: 26811494
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Afatinib-refractory brain metastases from EGFR-mutant non-small-cell lung cancer successfully controlled with erlotinib: a case report.
    Nonagase Y; Okamoto K; Iwasa T; Yoshida T; Tanaka K; Takeda M; Kaneda H; Shimizu T; Tsurutani J; Nakagawa K
    Anticancer Drugs; 2016 Mar; 27(3):251-3. PubMed ID: 26575001
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance.
    Saunus JM; Quinn MC; Patch AM; Pearson JV; Bailey PJ; Nones K; McCart Reed AE; Miller D; Wilson PJ; Al-Ejeh F; Mariasegaram M; Lau Q; Withers T; Jeffree RL; Reid LE; Da Silva L; Matsika A; Niland CM; Cummings MC; Bruxner TJ; Christ AN; Harliwong I; Idrisoglu S; Manning S; Nourse C; Nourbakhsh E; Wani S; Anderson MJ; Fink JL; Holmes O; Kazakoff S; Leonard C; Newell F; Taylor D; Waddell N; Wood S; Xu Q; Kassahn KS; Narayanan V; Taib NA; Teo SH; Chow YP; kConFab ; Jat PS; Brandner S; Flanagan AM; Khanna KK; Chenevix-Trench G; Grimmond SM; Simpson PT; Waddell N; Lakhani SR
    J Pathol; 2015 Nov; 237(3):363-78. PubMed ID: 26172396
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.
    Kim HS; Kwon HJ; Jung I; Yun MR; Ahn MJ; Kang BW; Sun JM; Kim SB; Yoon DH; Park KU; Lee SH; Koh YW; Kim SH; Choi EC; Koo DH; Sohn JH; Kim B; Kwon NJ; Yun HJ; Lee MG; Lee JH; Kim TM; Kim HR; Kim JH; Paik S; Cho BC
    Clin Cancer Res; 2015 Feb; 21(3):544-52. PubMed ID: 25424851
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. The ErbB/HER family of protein-tyrosine kinases and cancer.
    Roskoski R
    Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 2.